IRVINE, Calif., June 8, 2015 (GLOBE NEWSWIRE) -- Praxsyn Corporation's (OTCQB:PXYN) anticipated business plan for 2015 is to acquire a sister subsidiary retail community pharmacy and to purchase additional pharmacies. Mesa is also in the early stages of developing a program to supply medications and products to diabetic patients and anticipates the commencement of filling prescriptions by the end of the third quarter of 2015.
By expanding the number of pharmacies, Praxsyn believes they will be able to diversify and enlarge their range of products and their field of operations. The plans for a pharmacy acquisition, as well as the expansion into diabetic medications and products, fits with Praxsyn's business strategy of further diversifying their product lines as well as building and acquiring regional pharmacies.
"We are making key, target moves as we continue to grow our company, one of which is to be of service to patients who are suffering with diabetes," said Edward Kurtz, CEO of Praxsyn Corporation. "We plan to offer a variety of therapeutic products that meet the needs of diabetic patients."
About Praxsyn Corporation
Headquartered in Irvine, California, Praxsyn works to realize the vision of medical professionals to improve the lives of patients. Mesa Pharmacy, a wholly owned subsidiary, provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and medical clinics. Mesa has developed a series of topical creams, in different strengths, that provide the pain relief doctors seek for their patients. Additional company information can be found at www.praxsyn.com.
Forward-Looking Statements
Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) including but not limited to statements regarding the acquisition of pharmacies as well as being in the early stages of developing new diabetic medications and products, and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.